Keefe, Bruyette & Woods Downgrades Trustmark (TRMK) to Underperform; Cutting Estimates & PT
Get Alerts TRMK Hot Sheet
Price: $48.29 +0.02%
Rating Summary:
2 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Keefe, Bruyette & Woods downgraded Trustmark (NASDAQ: TRMK) to Underperform, price target cut from $23 to $21.
KBW analyst says, "4Q11 results missed consensus by 3c & core earnings (PTPP ROA) power declined meaningfully, thus we are reducing our '12 & '13 EPS estimates by $0.07 to $1.58 & $0.13 to $1.72. With the reduced cash flows we are lowering our price target to $21. While we believe TRMK is a quality franchise we believe the shares are currently fully valued and thus are lowering our rating."
For an analyst ratings summary and ratings history on Trustmark click here. For more ratings news on Trustmark click here.
Shares of Trustmark closed at $24.63 yesterday.
KBW analyst says, "4Q11 results missed consensus by 3c & core earnings (PTPP ROA) power declined meaningfully, thus we are reducing our '12 & '13 EPS estimates by $0.07 to $1.58 & $0.13 to $1.72. With the reduced cash flows we are lowering our price target to $21. While we believe TRMK is a quality franchise we believe the shares are currently fully valued and thus are lowering our rating."
For an analyst ratings summary and ratings history on Trustmark click here. For more ratings news on Trustmark click here.
Shares of Trustmark closed at $24.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
DowngradesRelated Entities
Keefe, Bruyette & Woods, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share